

Special Issue

Lentiviral Vectors

Message from the Guest Editor

Research on lentiviruses has been intensive and provided the basis for the development of lentiviral vector (LV) systems. While HIV-1-derived LV are routinely used in a wide range of basic biology research, recent advances leading to their clinical use. Research and development of LVs based on non-human lentivirus species, such as SIV and FIV, has also been substantial and the use of heterologous, non-lentiviral envelopes in LV systems relies on wider virology research. Additionally, clinical translation and development of LV systems to realize improved efficacy and safety requires multi-disciplinary efforts beyond virology to address key issues, such as biologics manufacturing, anti-LV host immune responses and LV-mediated genotoxicity. While LV development benefits from virologic and other research areas, it is noted that LV research can, in turn, provide valuable advanced research tools and insights as well as novel research ideas and questions. This special issue is calling for reviews and original papers in this wide area of research related to lentiviral vectors.

Guest Editor

Dr. Yasuhiro Takeuchi

Infection and Immunity, University College London (UCL): Advanced Therapies, National Institute for Biological Standards and Control (NIBSC), Hertfordshire, UK

Deadline for manuscript submissions

closed (31 March 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.6
Indexed in PubMed



mdpi.com/si/39904

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.6
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).